<DOC>
	<DOCNO>NCT00152581</DOCNO>
	<brief_summary>Open-label , single centre study evaluate efficacy viral kinetics combination PEG-IFNa2a Ribavirin treatment CHC genotype 1 patient , administer viral clearance demonstrate 4 – 12 week , randomise continued combination treatment one three define duration . Followed-up 24 week treatment cessation . Objectives : 1 . To determine necessary duration combination treatment Pegylated-Interferon alfa2a ( PEGASYS ) &amp; Ribavirin Patients infect genotype 1 , order achieve viral clearance 2 . To identify host factor , associate different pattern virological response combination treatment ( fast responder , slow responder , non-responder ) . On basis , identify possible predictor duration antiviral treatment .</brief_summary>
	<brief_title>Analysis Duration Combination Therapy That Necessary HCV Genotype 1 Eradication</brief_title>
	<detailed_description>Forty treatment-naïve patient chronic hepatitis C , infect genotype 1 , enter study . All 40 patient start regimen 180mg Pegylated-Interferon alfa2a ( PEGASYS ) weekly plus Ribavirin 1000-1200mg daily . HCV RNA serum monitor qualitative PCR treatment week 4 , 8 12 . Patients become HCV RNA negative time-points ( 4,8 12 ) , randomise one three group continue antiviral regimen additional 3 month , 6 month 9 month period . All patient subsequently followed-up monitored 6 month stop antiviral treatment . Treatment discontinue patient remain persistently HCV RNA positive treatment week 12 withdrawn study protocol .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age 18 – 65 HCV RNA positive HCV genotype 1 Histologically proven chronic hepatitis No previous antiviral treatment Liver histology show cirrhosis Decompensated liver function WCC &lt; 1500/mm3 platelet count &lt; 90,000/mm3 Coinfection HIV HBV/HAV Alcohol intake great 40 units/week Current intravenous drug dependence Pregnancy breast feeding infant Inadequate contraception Neuropsychiatric disorder Neoplastic disease Other significant medical problem</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>HCV , genotype 1 , treatment , HCV kinetics , T-cells</keyword>
</DOC>